Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma

被引：53

作者：

Liu, Yiwei ^{[1
]}

Dong, Zhengwei ^{[2
]}

Jiang, Tao ^{[1
]}

Hou, Likun ^{[2
]}

Wu, Fengying ^{[1
]}

Gao, Guanghui ^{[1
]}

He, Yayi ^{[1
]}

Zhao, Jing ^{[1
]}

Li, Xuefei ^{[3
]}

Zhao, Chao ^{[3
]}

Zhang, Wei ^{[2
]}

Tian, Qinrui ^{[1
]}

Pan, Yingying ^{[1
]}

Wang, Yan ^{[1
]}

Yang, Shuo ^{[1
]}

Wu, Chunyan ^{[2
]}

Ren, Shengxiang ^{[1
]}

Zhou, Caicun ^{[1
]}

Zhang, Jun ^{[4
]}

Hirsch, Fred R. ^{[5
]}

机构：

[1] Tongji Univ, Sch Med, Dept Med Oncol, Shanghai Pulm Hosp,Thorac Canc Inst, Shanghai 200433, Peoples R China

[2] Tongji Univ, Shanghai Pulm Hosp, Dept Pathol, Sch Med, 507 Zheng Min Rd, Shanghai 200433, Peoples R China

[3] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Lung Canc & Immunol, Shanghai 200433, Peoples R China

[4] Univ Iowa, Carver Coll Med, Div Hematol Oncol & Blood & Marrow Transplanta, Dept Internal Med,Holden Comprehens Canc Ctr, Iowa City, IA USA

[5] Univ Colorado, Canc Ctr, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA

来源：

CLINICAL LUNG CANCER | 2018年 / 19卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Concordance rate; Histologic feature; Lymph node metastasis; Programmed death-ligand 1; Tumor-infiltrating lymphocyte; DEATH-LIGAND; 1; PULMONARY SQUAMOUS-CELL; CLINICOPATHOLOGICAL ANALYSIS; TUMORS IMPACT; UP-REGULATION; CANCER; ADENOCARCINOMA; NSCLC; MUTATIONS; NIVOLUMAB;

D O I：

10.1016/j.cllc.2018.02.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this study, we investigated heterogeneity of programmed death-ligand 1 (PD-L1) expression and accordance of metastatic nodes. PD-L1 expression in 72 resected lung adenosquamous carcinoma and paired metastatic nodes was assessed. We found that PD-L1 expression was inconsistent in different histologic components within the tumor, and consistent in paired (primary and lymph node) histologic components. Introduction: Programmed death-ligand 1 (PD-L1) expression using immunohistochemistry is approved by the US Food and Drug Administration to guide treatment with anti-programmed death-1/PD-L1 monoantibodies. However, intratumoral heterogeneity of PD-L1 expression and the accordance between primary and metastatic lesions remains unresolved. Materials and Methods: PD-L1 expression was evaluated in tumor cells and tumor-infiltrating lymphocytes (TILs) of surgically resected lung adenosquamous carcinoma. Discrepancy of PD-L1 expression and cluster of differentiation 8-positive TILs of different histologic components was investigated. PD-L1 expression was also compared between primary tumor and nodal metastases. Results: The study included a total of 72 lung adenosquamous carcinomas. Fifteen patients (20.8%) and 25 patients (34.7%) were positive for PD-L1 expression in adenomatous and squamous components respectively, with a cutoff value of 5%. We found that 57.8% of cases showed consistent PD-L1 expression in tumor cells in the different histological components at a cutoff of 1%, and 48.1% of cases were likewise consistent at a cutoff of 5%. In paired squamous components of metastatic nodes and primary lesions, 90% and 80% of cases of PD-L1 expression were consistent, at cutoffs of 1% and 5%, respectively. For the adenomatous component of tumor/metastasis pairs, 77.8% of cases at the 1% cutoff and 74.1% of cases at the 5% cutoff were consistent, partially attributed to the difference of predominant histologic patterns. Conclusion: PD-L1 expression showed discrepancy in different histological components within a tumor and consistency in paired histological type between tumor and metastases. Different pathological features might contribute to the heterogeneous PD-L1 expression in patients with non-small-cell lung cancer. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：E421 / E430

页数：10

共 55 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].